Recommendations for treatment of complicated urinary tract infection in males

Principle: urinary tract infection in a male is, by convention, complicated. Contemporary practice replaces the term "acute prostatitis" with male urinary tract infection, managed as a "urinary infection at risk of complication". A lower UTI in a man is treated as prostatic infection.

Why complicated: older men have obstructive uropathy from prostatic enlargement, high residual urine, catheters, instrumentation, diabetes and structural abnormality — all of which predispose to relapse, abscess and bacteraemia.

Microbiology: Gram-negative bacilli predominate — Escherichia coli and Proteus species most commonly; also Klebsiella, Pseudomonas, enterococci and staphylococci. Recurrence after completing therapy is usually with the same organism.

Presentation ranges widely — from paucisymptomatic cystitis-like illness to spiking fever, chills, malaise, myalgia, dysuria, pelvic or perineal pain and cloudy urine. In older men, delirium, falls and functional decline may dominate.

Diagnosis: gentle digital rectal examination showing an oedematous tender prostate supports the diagnosis — vigorous prostatic massage must be avoided because it is painful, adds nothing diagnostically and risks bacteraemia. A dipstick positive for leukocytes or nitrites has a positive predictive value above 90% in a symptomatic man. Send urine Gram stain and culture in every case; the diagnostic threshold is ≥10³ CFU/mL with leukocyturia ≥10⁴/mL. Take blood cultures when there is fever. Do not measure PSA during a male UTI — it needs about six months to return to baseline.

Pharmacological principle: the barrier between the prostatic microcirculation and stroma permits only non-protein-bound, lipophilic antimicrobials to diffuse in, and the low pH of prostatic fluid allows drugs with alkaline pKa — quinolones and sulfonamides — to concentrate in prostatic tissue. Penetration improves in the presence of inflammation.

Route and setting: ambulatory, pauci-symptomatic men may be treated orally, guided by susceptibility results. Men with fever or signs of sepsis need hospitalisation and urgent empirical parenteral therapy, because Gram-negative bacteraemia can progress abruptly to life-threatening septic shock.

Antimicrobial choice:

Gram-negative bacilli, oral therapy: trimethoprim–sulfamethoxazole or a fluoroquinolone. Other agents with good to excellent prostatic penetration are tetracyclines, macrolides, sulfonamides and nitrofurantoin.

Parenteral therapy: an aminoglycoside combined with an intravenous cephalosporin or a fluoroquinolone; treat as Gram-negative infection until further culture data are available.

Gram-positive cocci in chains → enterococcal infection → amoxicillin.

Gram-positive cocci in clusters → Staphylococcus aureus or coagulase-negative staphylococci; when S. aureus is isolated from urine, always take blood cultures to confirm that the bacteriuria reflects local infection rather than seeding from bacteraemia.

Source control and supportive care: relieve obstruction (catheter or suprapubic drainage; nephrostomy or stent for upper-tract obstruction), remove or replace an infected catheter, drain a prostatic or perinephric abscess, maintain hydration, adjust doses for renal function, monitor for delirium and falls, and avoid nephrotoxins.

Duration and follow-up: treat for a prolonged course reflecting prostatic involvement — commonly 10–14 days, extended to several weeks where prostatic infection is established, and up to 4–6 weeks for chronic bacterial prostatitis. Investigate the urinary tract after the episode (ultrasound, PVR, and PSA deferred by about six months) and treat the underlying obstruction to prevent relapse.

New agents for complicated UTI: cefepime–enmetazobactam was FDA-approved in 2024 for complicated UTI including pyelonephritis, showing non-inferiority and superiority to piperacillin–tazobactam for clinical cure and microbiological eradication; cefepime–taniborbactam demonstrated superiority over meropenem in the phase-3 CERTAIN-1 trial (70.6% vs 58.0% composite response) but has faced regulatory delay on manufacturing grounds. Ceftazidime–avibactam, ceftolozane–tazobactam, meropenem–vaborbactam, plazomicin and cefiderocol remain the mainstay options for multidrug-resistant Gram-negative complicated UTI.

Gepotidacin (Blujepa), approved March 2025, is the first new oral antibiotic class for urinary infection in almost thirty years — but its licence is for uncomplicated UTI in females aged ≥12 years, not for complicated male UTI; it is a common examination distractor.

Fluoroquinolone restriction continues: regulatory warnings on tendinopathy, aortic aneurysm, neuropathy, delirium and dysglycaemia, together with high Indian resistance rates, mean quinolones should be guided by culture rather than used empirically in older men. ICMR AMR surveillance shows very high fluoroquinolone and third-generation cephalosporin resistance among urinary E. coli isolates in India, with carbapenem-sparing strategies now a national priority under the ICMR treatment guidelines and NAP-AMR.

Every UTI in a man is complicated; a lower UTI in a man is treated as prostatic infection.

Diagnostic threshold: ≥10³ CFU/mL with leukocyturia ≥10⁴/mL.

Avoid vigorous prostatic massage — risk of bacteraemia.

Do not check PSA during a male UTI; wait about six months.

Only lipophilic, non-protein-bound, alkaline-pKa drugs penetrate the prostate.

Fever or sepsis → admit and give parenteral therapy urgently.

S. aureus in the urine → take blood cultures.

Treat 10–14 days, longer for established prostatic infection; 4–6 weeks for chronic bacterial prostatitis.

Gepotidacin is licensed for uncomplicated UTI in women only — a classic distractor.

DRIP — Delirium · Restricted mobility/Retention · Infection, Inflammation, Impaction · Polyuria, Pharmaceuticals

DIAPPERS — Delirium · Infection · Atrophic vaginitis · Pharmaceuticals · Psychological · Excess urine output · Restricted mobility · Stool impaction

A-5-C-A-P (BPH medical therapy) — Alpha-blocker · 5-ARI · Combination · Anticholinergic/ β3 · PDE-5 inhibitor

AIMS (CAUTI bundle) — Avoid · Insert aseptically · Maintain closed system · Stop early

PROSTATE (male UI causes) — Prostatic obstruction · Radiotherapy/Radical prostatectomy

Overactive bladder · Stricture · Tumour · Autonomic neuropathy · Toxins/drugs · Environment Ten Traps That Cost Marks

Saying ageing causes incontinence — it only predisposes.

Omitting the post-void residual from the basic evaluation.

Treating asymptomatic bacteriuria in a catheterised or stable institutionalised patient.

Prescribing oral rather than topical oestrogen.

Adding an antimuscarinic in a man without checking the residual (DHIC and retention).

Forgetting that 5-α-reductase inhibitors halve PSA.

Missing that chronic obstructive uropathy causes polyuria, not oliguria.

Forgetting post-obstructive diuresis after relieving chronic retention.

Measuring PSA during an acute male urinary tract infection.

Using a catheter, condom drainage or pads for convenience rather than for an indication. Prepared as an examination revision aid. Clinical decisions must always be individualised, and local antibiograms and institutional protocols should guide antimicrobial choice.